Molecular Classification of Triple-Negative Breast Cancer

Tumor heterogeneity of triple-negative breast cancer (TNBC) has been the main barrier in conquering breast cancer. To dissect the molecular diversity of TNBC and discover therapeutic targets for TNBC, the molecular classification of TNBC is a prioritized issue in research area. Accordingly, recent studies have been successful in classifying TNBC into several distinct subtypes with specific biologic pathways. Despite the different methodologies used and varied number of final subtypes, these studies identically suggested that TNBC consists of four major subtypes: basal-like, mesenchymal, luminal androgen receptor, and immune-enriched. By reviewing these methods of classifications of TNBC, we highlight the unmet need to develop a molecular classifier suited for TNBC.

• Publication year

  2016

• Venue

  Journal of Breast Cancer

• Publication date

  2016-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4048/jbc.2016.19.3.223PMID 27721871PMCID 5053306
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer

  2016cited by this paper
• Implications for Therapy

  2016cited by this paper
• Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

  2015cited by this paper
• Gene-expression molecular subtyping of triple-negative breast cancer tumours: importance of immune response

  2015cited by this paper
• Subtyping of triple‐negative breast cancer: Implications for therapy

  2015cited by this paper
• Metastatic breast carcinomas display genomic and transcriptomic heterogeneity

  2015cited by this paper
• Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).

  2015cited by this paper
• Cisplatin plus gemcitabine versus paclitaxel plus gemcitabine as first-line therapy for metastatic triple-negative breast cancer (CBCSG006): a randomised, open-label, multicentre, phase 3 trial.

  2015cited by this paper
• Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)

  2015cited by this paper
• Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

  2015influential reference
• Fibroblast growth factor receptor splice variants are stable markers of oncogenic transforming growth factor β1 signaling in metastatic breast cancers

  2014cited by this paper
• Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial–mesenchymal transition (EMT) to mesenchymal–epithelial transition (MET) states

  2014cited by this paper
• Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

  2014cited by this paper
• Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer.

  2014cited by this paper
• BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD).

  2014cited by this paper
• Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

  2014influential reference
• Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypes

  2014cited by this paper
• PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors

  2014cited by this paper
• Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers

  2014cited by this paper
• The FGFR1 inhibitor PD173074 induces mesenchymal–epithelial transition through the transcription factor AP-1

  2013cited by this paper
• Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

  2013cited by this paper
• Prognostic Discrimination Using a 70-Gene Signature among Patients with Estrogen Receptor-Positive Breast Cancer and an Intermediate 21-Gene Recurrence Score

  2013cited by this paper
• Phase II Trial of Bicalutamide in Patients with Androgen Receptor–Positive, Estrogen Receptor–Negative Metastatic Breast Cancer

  2013cited by this paper
• TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer

  2012influential reference
• Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

  2011influential reference
• Triple-negative breast cancer.

  2010cited by this paper
• Triple-negative breast cancer.

  2008cited by this paper
• Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas

  2007cited by this paper
• Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer.

  2006cited by this paper
• Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

  2005cited by this paper
• Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

  2005cited by this paper
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials.

  2005cited by this paper
• Selection of adjuvant chemotherapy for treatment of node-positive breast cancer.

  2005cited by this paper
• Global Cancer Statistics, 2002

  2005cited by this paper
• Molecular portraits of human breast tumours

  2000cited by this paper

• Emerging Targeted and Multimodal Therapeutic Strategies in Breast Cancer: A Comprehensive Review

  2026cites this paper
• Contribution of Mesenchymal-like and Epithelial Cellular Subsets to Chemotherapy Resistance in Triple-Negative Breast Cancer

  2025cites this paper
• Value-Based Pricing for Drugs With Uncertain Clinical Benefits.

  2025cites this paper
• Co-delivery of copper chelators and glycolytic inhibitors to disrupt glucose metabolism and inhibit tumor metastasis

  2025cites this paper
• Toward precision oncology in LUAD: a prognostic model using single-cell sequencing and WGCNA based on a disulfidptosis relative gene signature

  2025cites this paper
• Mapping molecular landscapes in triple-negative breast cancer: insights from spatial transcriptomics

  2025cites this paper
• Low Expression of UBE2Z, a Target Protein of miR-500a, Is Associated with Poor Prognosis in Triple-Negative Breast Cancer

  2025cites this paper
• Breast Cancer Immunotherapy: A Team Science Approach.

  2025cites this paper
• The search for a TNBC vaccine: the guardian vaccine

  2025cites this paper
• Emerging Breast Cancer Subpopulations: Functional Heterogeneity Beyond the Classical Subtypes

  2025cites this paper
• Genetic and epigenetic alterations in human cancers

  2024cites this paper
• Prognostic and immunotherapeutic potential of regulatory T cell‐associated signature in ovarian cancer

  2024cites this paper
• Concurrent vs. Sequential Adjuvant Capecitabine-Based Chemoradiation in Residual TNBC after neoadjuvant-chemotherapy: A Multicenter comparative Study.

  2024cites this paper
• LINC00668 silencing retards tumorigenesis via sponging miR-518c-3p to regulating WDR1 in triple negative breast cancer.

  2024cites this paper
• Management of triple-negative breast cancer by natural compounds through different mechanistic pathways

  2024cites this paper
• IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells

  2024cites this paper
• Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies

  2024cites this paper
• Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype

  2024cites this paper
• Cu superparticle-based aggregation induced enhancement strategy with PVDF-HFP/CeVO4 NP sensing interface for miR-103a detection.

  2024cites this paper
• Targeting Pivotal Hallmarks of Cancer for Enhanced Therapeutic Strategies in Triple-Negative Breast Cancer Treatment—In Vitro, In Vivo and Clinical Trials Literature Review

  2024influential citation
• Clinical Advances in Triple Negative Breast Cancer Treatment: Focus on Poly (L-lactide-coglycolide) Nanoparticles

  2024cites this paper
• Caffeine Increased Antitumor Effects of Paclitaxel (PTX) in MCF-7 and MDA-MB-231 Breast Cancer Cells

  2023cites this paper
• Triple Negative Breast Cancers: An Obsolete Entity?

  2023cites this paper
• Interaction of phenotypic sublines isolated from triple-negative breast cancer cell line MDA-MB-231 modulates their sensitivity to paclitaxel and doxorubicin in 2D and 3D assays.

  2023cites this paper
• Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges

  2023cites this paper
• Asymmetric Heterodimer-Regulated Surface Plasmon Coupling ECL Polarization Strategy for MiRNA-182 Detection.

  2023cites this paper
• Retrospective study of transcriptomic profiling identifies Thai triple-negative breast cancer patients who may benefit from immune checkpoint and PARP inhibitors

  2023cites this paper
• Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma

  2023cites this paper
• Drug Target Identification in Triple Negative Breast Cancer Stem Cell Pathways: a computational study of gene regulatory pathways using Boolean networks

  2023cites this paper
• Regulation of Inflammasome by microRNAs in Triple-Negative Breast Cancer: New Opportunities for Therapy

  2023cites this paper
• Transcriptomic profiles‐based approach to decode the role of miR‐122 in triple negative breast cancer

  2023cites this paper
• Myricetin-induced apoptosis in triple-negative breast cancer cells through inhibition of the PI3K/Akt/mTOR pathway

  2022cites this paper
• Covalent JNK inhibitor, JNK-IN-8, suppresses tumor growth in triple-negative breast cancer by activating TFEB and TFE3 mediated lysosome biogenesis and autophagy.

  2022cites this paper
• Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

  2022cites this paper
• Newly Developed Targeted Therapies Against the Androgen Receptor in Triple-Negative Breast Cancer: A Review

  2022cites this paper
• Aspectos clínicos y terapéuticos del carcinoma de mama metastásico triple negativo

  2022cites this paper
• Reduced CREB3L1 expression in triple negative and luminal a breast cancer cells contributes to enhanced cell migration, anchorage-independent growth and metastasis

  2022cites this paper
• Hypermethylation of TMEM240 predicts poor hormone therapy response and disease progression in breast cancer

  2022cites this paper
• Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line

  2022influential citation
• Effect, Mechanism, and Applications of Coding/Non-coding RNA m6A Modification in Tumor Microenvironment

  2021cites this paper
• A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer

  2021cites this paper
• Androgen receptor expression and outcome of neoadjuvant chemotherapy in triple-negative breast cancer.

  2021cites this paper
• Molecular Prognostic and Predictive Markers in Triple - Negative Breast Cancer

  2021cites this paper
• Germline and Somatic Mutations in Archived Breast Cancer Specimens of Different Subtypes

  2021cites this paper
• Overekspresi Androgen Receptor (AR) sebagai Faktor Prediktif Respon Klinis Kemoterapi Neoadjuvan Negatif pada Triple Negative Breast Cancer

  2021cites this paper
• The Orai1-AC8 Interplay: How Breast Cancer Cells Escape from Orai1 Channel Inactivation

  2021cites this paper
• Targeting of lactate dehydrogenase C dysregulates the cell cycle and sensitizes breast cancer cells to DNA damage response targeted therapy

  2021cites this paper
• Determining Factors in the Therapeutic Success of Checkpoint Immunotherapies against PD-L1 in Breast Cancer: A Focus on Epithelial-Mesenchymal Transition Activation

  2021cites this paper
• Targeting LDHC dysregulates the cell cycle and improves sensitivity to cisplatin and olaparib

  2021cites this paper
• Triple-negative breast cancer: A run-through of features, classification and current therapies

  2021cites this paper
• Luminal A breast cancer resistance mechanisms and emerging treatments

  2021cites this paper
• CXCR2 Levels Correlate with Immune Infiltration and a Better Prognosis of Triple-Negative Breast Cancers

  2021cites this paper
• Clinical and morphological factors associated with two groups of concordant breast cancer immunophenotypes: a cross-sectional study of 24-year historical series

  2021cites this paper
• Involvement of Par-4 in Breast Cancer

  2021cites this paper
• Emerging Role of PARP Inhibitors in Metastatic Triple Negative Breast Cancer. Current Scenario and Future Perspectives

  2021cites this paper
• Matched cohort study of germline BRCA mutation carriers with triple negative breast cancer in brightness

  2021cites this paper
• The role of immune checkpoint inhibitors in triple-negative breast cancer: recent developments and future perspectives

  2021cites this paper
• . Invasive ductal breast carcinoma: morphological features of molecular subtypes

  2021cites this paper
• EGFR, BRCA1, BRCA2 and TP53 genetic profile in Moroccan triple negative breast cancer cases.

  2020cites this paper
• AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells

  2020cites this paper
• G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer

  2020cites this paper
• A Modified Lentivirus-Based Reporter for Magnetic Separation of Cancer Stem Cells

  2020cites this paper
• Lysyl Oxidase Like‐2 (LOXL2): An Emerging Oncology Target

  2020cites this paper
• Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies

  2020cites this paper
• ID4 Promotes Breast Cancer Chemotherapy Resistance via CBF1-MRP1 Pathway

  2020cites this paper
• CLCA2 expression is associated with survival among African American women with triple negative breast cancer

  2020cites this paper
• Effect of Bicalutamide on the proliferation and invasion of human triple negative breast cancer MDA-MB-231 cells

  2020cites this paper
• EVALUATION OF P53 AND KI67 PROLIFERATIVE INDEX IN TRIPLE NEGATIVE BREAST CARCINOMA

  2020cites this paper
• REVIEW ON POTENTIAL TARGETED THERAPY FOR TRIPLE NEGATIVE BREAST CANCER

  2020cites this paper
• A novel prognostic two-gene signature for triple negative breast cancer

  2020cites this paper
• [A Modified Lentivirus-Based Reporter for Magnetic Separation of Cancer Stem Cells].

  2020cites this paper
• Epithelial–Mesenchymal Transition Programs and Cancer Stem Cell Phenotypes: Mediators of Breast Cancer Therapy Resistance

  2020cites this paper
• Current trends and opportunities in targeting p21 activated kinase-1(PAK1) for therapeutic management of breast cancers.

  2020cites this paper
• Transcriptome-Based Network Analysis Unveils Eight Immune-Related Genes as Molecular Signatures in the Immunomodulatory Subtype of Triple-Negative Breast Cancer

  2020influential citation
• 18F-fluorodeoxyglucose uptake on PET/computed tomography in association with androgen receptor expression and other clinicopathologic factors in surgically resected triple-negative breast cancer

  2020cites this paper
• Molecular subtypes of triple-negative breast cancer: understanding of subtype categories and clinical implication

  2020cites this paper
• Breast Cancer is not Just One Disease: A special focus of molecular heterogeneity of Triple Negative Breast Cancer

  2020cites this paper
• Neoadjuvant Chemotherapy for Breast Cancer: Past, Present, and Future

  2020cites this paper
• Investigation of Intra-tumour Heterogeneity and Host Immune Response in Triple-negative Breast Cancer

  2020cites this paper
• Single Nucleotide Polymorphisms Influence Histological Type and Grade of Canine Malignant Mammary Tumours.

  2019cites this paper
• Heterogeneity of breast cancer: the importance of interaction between different tumor cell populations.

  2019cites this paper
• Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer

  2019cites this paper
• Serum amyloid A predisposes inflammatory tumor microenvironment in triple negative breast cancer

  2019cites this paper
• Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology

  2019cites this paper
• Biologic and Therapeutic Studies to Improve the Anti-tumor Efficacy of Antiangiogenic Tyrosine Kinase Inhibitors

  2019cites this paper
• Prevention of Breast Cancer by Food Bioactives in Relation to Cancer Subtypes

  2019cites this paper
• Triple-negative breast cancer-derived microvesicles transfer microRNA221 to the recipient cells and thereby promote epithelial-to-mesenchymal transition

  2019cites this paper
• Dancing from bottoms up - Roles of the POZ-ZF transcription factor Kaiso in Cancer.

  2019cites this paper
• Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women

  2019cites this paper
• Significant Clinical Activity of Olaparib in a Somatic BRCA1-Mutated Triple-Negative Breast Cancer With Brain Metastasis.

  2019cites this paper
• Assessing the Role of the Interleukin-12/STAT4 Axis in Breast Cancer by a Bioinformatics Approach.

  2019cites this paper
• Identification of three subtypes of triple-negative breast cancer with potential therapeutic implications

  2019cites this paper
• Consequences of EMT-Driven Changes in the Immune Microenvironment of Breast Cancer and Therapeutic Response of Cancer Cells

  2019cites this paper
• Genomic Characteristics of Triple-Negative Breast Cancer Nominate Molecular Subtypes That Predict Chemotherapy Response

  2019cites this paper
• Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms

  2019cites this paper
• Androgen receptor in triple negative breast cancer: A potential target for the targetless subtype.

  2018cites this paper
• Rôle de la protéine immuno-régulatrice PD-L1 sur le métabolisme des cellules tumorales

  2018cites this paper
• THE ROLE OF IMMUNE EFFECTOR CELLS IN THE 4T1.2 MURINE MAMMARY TUMOR MODEL

  2018cites this paper
• Study of the antitumor potential of natural Products and curcumin-loaded PLGA Nanoparticles in human breast cell lines

  2018influential citation
• Tagalide A and tagalol A, naturally occurring 5/6/6/6- and 5/6/6-fused cyclic dolabrane-type diterpenes: a new insight into the anti-breast cancer activity of the dolabrane scaffold

  2018cites this paper